ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsAndrew J. Souers, Steven W. Elmore, Peter Kovar et al.|Nature Medicine|2013Cited by 3k
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family InhibitorChristin Tse, Steven W. Elmore, Alexander R. Shoemaker et al.|Cancer Research|2008Cited by 2k
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor ModelsCherrie K. Donawho, David J. Frost, Yan Luo et al.|Clinical Cancer Research|2007Cited by 770
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 ProteinsCheol‐Min Park, Steven W. Elmore, Milan Bruncko et al.|Journal of Medicinal Chemistry|2008Cited by 293
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft ModelsAlex R. Shoemaker, Steven W. Elmore, Michael J. Mitten et al.|Clinical Cancer Research|2008Cited by 209